To support development of new therapeutic possibilities, manufacturing and process development technologies must also evolve. For antibody variants, platform purification protocols for conventional mAb aren’t always providing sufficient outputs — some variants need new ligands, new base matrices, or new chromatography systems, or they have different regulatory requirements, or application needs.
In this video Josefin Bolik, global product manager — antibody capture at Cytiva, presents how to select resins for your antibody variant purification project.